EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis

Damian J Ralser, Verena Kiver, Erich-Franz Solomayer, Caroline Neeb, Jens-Uwe Blohmer, Alina V Abramian, Nicolai Maass, Florian Schütz, Cornelia Kolberg-Liedtke, Carolin Müller, Anna-Christina Rambow

Archives of Gynecology and Obstetrics · 07.10.2024 · 311 (2) · 423-427

DOI: 10.1007/s00404-024-07761-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Archives of Gynecology and Obstetrics, online erschienen am 07.10.2024. Verfasst von Damian J Ralser und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Gynecological Oncology, University Hospital Bonn, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germa…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BONFOR, DFG, Universitätsklinikum Bonn.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

CDK4/6 inhibitors (CDK4/6i) represent the first-line therapy approach of choice for patients with hormone receptor-positive, HER2-negative advanced breast cancer (HR + /HER-ABC). Approximately 50% of HR + /HER2-ABC displays low HER2 expression (HER2 low). Recent data emerging from the DESTINY-Breast04 trial demonstrated practice-changing efficacy of the antibody–drug conjugate trastuzumab deruxtecan (T-DXd) in patients with low HER2 expression. Here, we aimed to analyze the impact of low HER2 expression on CDK4/6i therapy response in a well-characterized multicenter HR + /HER-ABC cohort.

Methods

Patients diagnosed with HR + /HER2-ABC who were treated with CDK4/6i in clinical routine between November 2016 and December 2020 at four certified German Breast Cancer Centers were retrospectively identified. The cohort was stratified according to graduation of positivity in HER2 immunohistochemistry (IHC; HER2 zero = IHC score 0 and HER2 low = IHC score 1 + , 2 + /fluorescence in situ hybridization negative). Subgroups were analyzed with regard to progression-free survival (PFS) following CDK4/6i initiation.

Findings

The study cohort comprised n = 448 patients. For n = 311 patients, HER2 status from the metastatic site was available. n = 91 (29.3%) cases were HER2 zero and n = 220 cases (70.7%) were HER2 low. There was no significant difference in PFS between the two groups (PFS: 17 months versus 18 months, log-rank p = 0.42). Further, we examined the influence of HER2 expression changes between primary and metastatic tissue ( n = 171; HER2 gain/HER2 loss/HER2 stable expression) on CDK4/6i treatment response. Again, there was no significant difference between these three groups, respectively (PFS: 16 months versus 13 months versus 17 months, log-rank p = 0.86).

Conclusions

In our analysis, HER2 status did not have a significant impact on treatment response to CDK4/6i.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Protein Kinase InhibitorsHumansFemaleMiddle AgedRetrospective StudiesAgedAdultTrastuzumabReceptors, EstrogenAged, 80 and overCamptothecinImmunoconjugates

Stichwörter der Autor:innen

Breast cancerCDK4/6 inhibitorHER2 lowTrastuzumab deruxtecan

Substanzen

Erb-b2 Receptor Tyrosine KinasesCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6TrastuzumabProtein Kinase InhibitorsReceptors, EstrogenCamptothecinImmunoconjugatesERBB2 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • Department of Gynecology and Gynecological Oncology, University Hospital Bonn, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany. damian.ralser@ukbonn.de.
  • Department of Gynecology With Breast Center, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität Zu Berlin, Charitéplatz 1, 10117, Berlin, Germany.
  • Department of Gynecology, Obstetrics & Reproductive Medicine, Saarland University Medical Center, Homburg, Saar, Germany.
  • Department of Gynecology and Gynecological Oncology, University Hospital Bonn, University Medical Center Bonn, Venusberg-Campus 1, 53127, Bonn, Germany.
  • Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein (UKSH), Campus Kiel, Kiel, Germany.
  • Department of Gynecology and Obstetrics, Diakonissen-Stiftungs-Krankenhaus Speyer, Speyer, Germany.

Förderung

  • BONFOR
  • DFG
  • Universitätsklinikum Bonn

Zitieren

APA

Ralser, D. J., Kiver, V., Solomayer, E. F., Neeb, C., Blohmer, J. U., Abramian, A. V., Maass, N., Schütz, F., Kolberg-Liedtke, C., Müller, C., & Rambow, A. C. (2024). Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis. Archives of Gynecology and Obstetrics, 311(2), 423-427. https://doi.org/10.1007/s00404-024-07761-2

Vancouver

Ralser DJ, Kiver V, Solomayer EF, Neeb C, Blohmer JU, Abramian AV, et al. Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis. Archives of Gynecology and Obstetrics. 2024;311(2):423-427. doi:10.1007/s00404-024-07761-2

BibTeX
@article{Ralser2024,
  author = {Ralser, Damian J and Kiver, Verena and Solomayer, Erich-Franz and Neeb, Caroline and Blohmer, Jens-Uwe and Abramian, Alina V and Maass, Nicolai and Schütz, Florian and Kolberg-Liedtke, Cornelia and Müller, Carolin and Rambow, Anna-Christina},
  title = {Impact of low HER2 expression on response to CDK4/6 inhibitor treatment in advanced HR + /HER2- breast cancer: a multicenter real-world data analysis},
  journal = {Archives of Gynecology and Obstetrics},
  year = {2024},
  volume = {311},
  number = {2},
  pages = {423--427},
  doi = {10.1007/s00404-024-07761-2}
}
Kostenlos starten →